Furthermore, the growth of renal cell carcinoma (Gemmill et al, 2005), glioblastoma multiforme (Goudar et al, 2005), as well as non-small-cell lung cancer, pancreatic, colon, and breast (Buck et al, 2006) cancers were synergistically reduced when EGFR inhibitors were combined with the mTOR inhibitor rapamycin. This evidence concerns the gene EGFR and non-small cell lung carcinoma.